Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Neurology. 2006 Oct 10;67(7):1262-4.

    Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.

    Source

    Department of Neurology, Klinikum Grosshadern, Klinikum Grosshadern, University of Munich, Germany.

    Abstract

    Mitochondrial dysfunction plays a major role in the pathogenesis of Parkinson disease (PD). Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD. We conducted a 2-year placebo-controlled randomized clinical trial on the effect of Cr in 60 patients with PD. Cr improved patient mood and led to a smaller dose increase of dopaminergic therapy but had no effect on overall Unified Parkinson's Disease Rating Scale scores or dopamine transporter SPECT.

    PMID:
    17030762
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for HighWire

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk